StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
RGNTREGENTIS BIOMATERIALS LTD.
stockpulse.co.kr
NYSE
$1.30▲ 1.56%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.1MShares out 7.0M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

6
  • 10.13Pre-market26.10.13 19:08
    6-KKey event#●●●#●●●

    REGENTIS BIOMATERIALS LTD.

    Regentis Biomaterials reported strong interest from orthopedic surgeons in its cell-free hydrogel implant, GelrinC, at the 8th ICRS Summit in Portugal. GelrinC is CE Mark approved in Europe, where the company is expanding its commercialization efforts, while its pivotal U.S. FDA Phase III trial has surpassed 50% enrollment.…more

    $1.30+1.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.23Pre-market26.09.23 13:15filed
    EFFECTOther

    REGENTIS BIOMATERIALS LTD.

    The registration statement for REGENTIS BIOMATERIALS LTD. became effective with the SEC on September 22, 2026. This notice confirms that the company's submitted registration documents have been approved, completing the legal requirements for potential capital raising or securities issuance.…more

    $1.30+1.56%vs prev close
    View filingShare
  • 9.17After-hours26.09.18 05:30
    POS AMOther

    REGENTIS BIOMATERIALS LTD.

    Regentis Biomaterials has filed a post-effective amendment to its registration statement for the resale of up to 3,807,143 ordinary shares. These shares consist of ordinary shares, pre-funded warrants, ordinary warrants, and placement agent warrants issued in a private placement that closed in June 2026.…more

    $1.30+1.56%vs prev close
    View filingShare

5 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.11Pre-market26.09.11 22:16
    #●●●#●●●

    Regentis Biomaterials H1 EPS Loss Narrows to $(0.44)

    Regentis Biomaterials reported a quarterly loss of $(0.44) per share, showing an improvement from the $(1.17) loss in the same period last year. While the loss has narrowed, the company remains in a loss-making position.…more

    $1.30+1.56%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga